|
2006P-0397:
Permit an ANDA Suitability for Fexofenadine Hydrochloride for Oral
Suspension
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Document #
|
| Received Date
|
| Filed
Date
|
| Submitter Code
|
| Submitter
|
| FR
Date
|
| FR
Page
|
| Comment Date
|
| Files
|
| Remarks
|
|
|
|
|
|
| |
CP1 |
|
09/29/2006
|
|
09/29/2006
|
|
Private Industry
|
|
Lupin Pharmaceuticals,
Inc. |
|
|
|
|
|
|
|
Table
of Contents |
|
|
|
| |
Signature: |
|
Leslie Sands |
|
| |
| |
ACK1 |
|
09/29/2006
|
|
09/29/2006
|
|
Federal Government |
|
FDA/ DDM to
Lupin Pharmaceuticals, Inc. |
|
|
|
|
|
|
|
pdf |
|
|
|
| |
|
|
Signature: |
|
Jennie C. Butler
|
|
| |
| |
EC1 |
|
10/05/2006
|
|
10/04/2006
|
|
Individual Consumer
|
|
Mr. Dave Lowe
|
|
|
|
|
|
|
|
htm
Attachment |
|
|
|
|
|
| C1
|
| 12/22/2006
|
| 12/21/2006
|
| Private Industry
|
| Sanofi-Aventis, U.
S. (Sanofi)
|
|
|
|
|
|
|
| pdf
|
|
|
|
|
| Signature:
|
| Peter O. Safir
| |
|
Top | Up Page last updated:
March 6, 2007
|
